Oncovir, Inc.

New York, New York

OncologyvaccinePhase I

What changed

Phase I trial registered: Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma

Jun 2025Trial registeredJun 24, 2025Source filing (opens the source filing in a new tab)

Momentum

48no change

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase I

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Grant
R01 · $680k · non-dilutive
Mar 1, 2025
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MERAD, MIRIAM · NCI · award ends Feb 28, 2030 · Dissecting the hematopoietic pathways governing age-associated pathogenic myelopoiesis
NIH RePORTER · NIH RePORTER 11107779 (opens the source filing in a new tab)
Grant
R01 · $658k · non-dilutive
May 2, 2023
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MERAD, MIRIAM · NCI · award ends Apr 30, 2028 · Type 2 immunity: a primitive response to epithelial injury that shapes bone marrow and lung myeloid crosstalk
NIH RePORTER · NIH RePORTER 11085274 (opens the source filing in a new tab)
Trial
PHASE1 registered
Aug 19, 2020
Malignant Pleural Mesothelioma · COMPLETED · sponsor: Oncovir, Inc. · Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma
ClinicalTrials.gov · NCT04525859 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["principal investigator MERAD, MIRIAM is named on this company's filings"]}
new_entity links the trial record at 0.22{"reasons":["no candidate cleared the review threshold"]}

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase I trial registered: Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma
Jun 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma
Jun 2025Trial completedSource (opens the source filing in a new tab)
NIH R01 · $0.7M · Type 2 immunity: a primitive response to epithelial injury that shapes bone marrow and lung myeloid crosstalk
Apr 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.7M · Dissecting the hematopoietic pathways governing age-associated pathogenic myelopoiesis
Feb 2025New grantSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

R01 · $680k · non-dilutive

R01 · $658k · non-dilutive

PHASE1 registered